Patent · US Active

Use of 2 anti-SPARC antibodies to predict response to chemotherapy for pancreatic adenocarcinoma

US9091697B2 · kind B2 · utility

0Cited by
3References
3Claims
0Family size

Assignee

Inventors

Key dates

Filing dateFeb 25, 2013
Grant dateJul 28, 2015
Priority date—
Expiry dateFeb 28, 2033

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2800/52
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The invention provides anti-SPARC antibody-based techniques for predicting a response to chemotherapy.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.